Literature DB >> 19704065

Professionals assess the acceptability of preimplantation genetic diagnosis and prenatal diagnosis for managing inherited predisposition to cancer.

Claire Julian-Reynier1, Françoise Chabal, Thierry Frebourg, Didier Lemery, Catherine Noguès, Francis Puech, Dominique Stoppa-Lyonnet.   

Abstract

PURPOSE: Preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND) practices for inherited predisposition to cancer are heterogeneous in industrialized countries. In France, permission to perform PGD/PND must be obtained from registered Multidisciplinary Prenatal Diagnosis Teams (MPDTs). The aim of this study was to determine French professionals' attitudes about the acceptability of PGD and PND for inherited predisposition to cancer.
METHODS: A cross-sectional survey was performed, involving self-administered questionnaires mailed to all registered cancer geneticists (CGs; n = 123) and MPDTs (n = 47) in France.
RESULTS: The response rates of CGs and MPDTs were 62% and 64%, respectively; 59% and 50% of the CGs had at least discussed PGD and PND, respectively, with their consultees during the previous year. When severe cancer is liable to occur in childhood with a high penetrance and no effective methods of prevention/treatment exist, high rates of acceptability of PGD/PND were recorded (> 80%). When cancer is liable to occur before the age of 50 years but not in childhood and some form of prevention/treatment is available that preserves quality of life, PGD was rated as acceptable by one MPDT (3.3%) and 10 CGs (13.2%), and PND was rated acceptable by nine CGs (11.8%). Most respondents agreed that the acceptability of PND/PGD depends on patients' family history of cancer and their reproductive history.
CONCLUSION: With the most severe forms of inherited cancer, no differences were observed between the acceptability to practitioners of PND and PGD, but with late-onset syndromes, there is still much uncertainty. Guidelines would help to standardize the practices of professionals handling these reproductive issues.

Entities:  

Mesh:

Year:  2009        PMID: 19704065     DOI: 10.1200/JCO.2008.21.2712

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

1.  Preimplantation genetic diagnosis for inherited breast cancer: first clinical application and live birth in Spain.

Authors:  Teresa Ramón Y Cajal; Ana Polo; Olga Martínez; Carles Giménez; César Arjona; Gemma Llort; Lluís Bassas; Pere Viscasillas; Joaquin Calaf
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

2.  Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options.

Authors:  Jacqueline Duffour; Audrey Combes; Evelyne Crapez; Florence Boissière-Michot; Frédéric Bibeau; Pierre Senesse; Marc Ychou; Julie Courraud; Hélène de Forges; Lise Roca
Journal:  J Genet Couns       Date:  2015-09-22       Impact factor: 2.537

3.  Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers.

Authors:  Efrat Dagan; Daphna Birenbaum-Carmeli; Eitan Friedman; Baruch Feldman
Journal:  J Genet Couns       Date:  2017-03-06       Impact factor: 2.537

4.  Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis.

Authors:  Elizabeth Ormondroyd; Louise Donnelly; Clare Moynihan; Cornelie Savona; Elizabeth Bancroft; D Gareth Evans; Rosalind Eeles; Stuart Lavery; Maggie Watson
Journal:  Eur J Hum Genet       Date:  2011-08-03       Impact factor: 4.246

5.  Views of internists towards uses of PGD.

Authors:  Robert Klitzman; Wendy Chung; Karen Marder; Anita Shanmugham; Lisa J Chin; Meredith Stark; Cheng-Shiun Leu; Paul S Appelbaum
Journal:  Reprod Biomed Online       Date:  2012-11-21       Impact factor: 3.828

6.  Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes.

Authors:  Amanda C Brandt; Matthew L Tschirgi; Kaylene J Ready; Charlotte Sun; Sandra Darilek; Jacqueline Hecht; Banu K Arun; Karen H Lu
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

7.  Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.

Authors:  Karen Hurley; Lisa R Rubin; Allison Werner-Lin; Michal Sagi; Yelena Kemel; Rikki Stern; Aliza Phillips; Ina Cholst; Noah Kauff; Kenneth Offit
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

8.  Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.

Authors:  Dorothea Gadzicki; D Gareth Evans; Hilary Harris; Claire Julian-Reynier; Irmgard Nippert; Jörg Schmidtke; Aad Tibben; Christi J van Asperen; Brigitte Schlegelberger
Journal:  J Community Genet       Date:  2011-03-02

9.  Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes.

Authors:  Thereasa A Rich; Mei Liu; Carol J Etzel; Sarah A Bannon; Maureen E Mork; Kaylene Ready; Devki S Saraiya; Elizabeth G Grubbs; Nancy D Perrier; Karen H Lu; Banu K Arun; Terri L Woodard; Leslie R Schover; Jennifer K Litton
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

10.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.